AnaptysBio, Inc. – NASDAQ:ANAB
AnaptysBio stock price today
$19.79
+6.75
+51.76%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
AnaptysBio stock price monthly change
-56.68%
month
AnaptysBio stock price quarterly change
-56.68%
quarter
AnaptysBio stock price yearly change
-40.35%
year
AnaptysBio key metrics
Market Cap | 434.52M |
Enterprise value | 551.76M |
P/E | -4.79 |
EV/Sales | 53.63 |
EV/EBITDA | -5.24 |
Price/Sales | 58.67 |
Price/Book | 2.30 |
PEG ratio | 0.04 |
EPS | -6.14 |
Revenue | 22.96M |
EBITDA | -145.43M |
Income | -163.3M |
Revenue Q/Q | 422.48% |
Revenue Y/Y | 114.77% |
Profit margin | -1251.33% |
Oper. margin | -1119.41% |
Gross margin | 0% |
EBIT margin | -1119.41% |
EBITDA margin | -633.37% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAnaptysBio stock price history
AnaptysBio stock forecast
AnaptysBio financial statements
Average Price Target
$55.33
Potential upside: 179.60%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 3.46M | -39.84M | -1151.59% |
|---|---|---|---|
| Sep 2023 | 3.31M | -37.30M | -1124.41% |
| Dec 2023 | 9.00M | -42.21M | -468.75% |
| Mar 2024 | 7.17M | -43.93M | -612.01% |
| 2024-03-11 | -1.74 | -1.59 |
|---|
| Jun 2023 | 517100000 | 368.65M | 71.29% |
|---|---|---|---|
| Sep 2023 | 487326000 | 366.94M | 75.3% |
| Dec 2023 | 452389000 | 364.28M | 80.52% |
| Mar 2024 | 405835000 | 358.05M | 88.23% |
| Jun 2023 | -25.40M | -20.45M | -13.49M |
|---|---|---|---|
| Sep 2023 | -36.47M | 30.63M | -3.07M |
| Dec 2023 | -34.34M | 49.17M | -5.15M |
| Mar 2024 | -44.19M | 68.61M | -6.69M |
AnaptysBio alternative data
| Aug 2023 | 96 |
|---|---|
| Sep 2023 | 96 |
| Oct 2023 | 96 |
| Nov 2023 | 96 |
| Dec 2023 | 96 |
| Jan 2024 | 96 |
| Feb 2024 | 96 |
| Mar 2024 | 117 |
| Apr 2024 | 117 |
| May 2024 | 117 |
| Jun 2024 | 117 |
| Jul 2024 | 117 |
AnaptysBio other data
100.00%
0.00%
of ANAB is owned by hedge funds
128
-6
29.73M
+1.97M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 16970 |
| Feb 2024 | 0 | 5000 |
| Mar 2024 | 0 | 148940 |
| May 2024 | 0 | 1500 |
| Jun 2024 | 0 | 3900 |
| Jul 2024 | 0 | 11500 |
| Aug 2024 | 273972 | 2000 |
| Sep 2024 | 0 | 28440 |
| Nov 2024 | 0 | 10000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | RENTON HOLLINGS director | Common Stock | 10,000 | $6.93 | $69,300 | ||
Option | RENTON HOLLINGS director | Common Stock | 10,000 | $6.93 | $69,300 | ||
Sale | RENTON HOLLINGS director | Common Stock | 10,000 | $25 | $250,000 | ||
Option | LIZZUL PAUL F. officer: Chief Me.. | Common | 1,500 | $18.5 | $27,750 | ||
Option | LIZZUL PAUL F. officer: Chief Me.. | Common Stock | 1,500 | $18.5 | $27,750 | ||
Sale | LIZZUL PAUL F. officer: Chief Me.. | Common Stock | 1,500 | $38.67 | $58,005 | ||
Sale | LOUMEAU ERIC J officer: CHIEF LEGAL OFFICER | Common Stock | 3,780 | $38.41 | $145,190 | ||
Option | LOUMEAU ERIC J officer: CHIEF LEGAL OFFICER | Employee Stock Option (right to buy) | 5,000 | $14.02 | $70,100 | ||
Option | LOUMEAU ERIC J officer: CHIEF LEGAL OFFICER | Common Stock | 5,000 | $14.02 | $70,100 | ||
Sale | LOUMEAU ERIC J officer: CHIEF LEGAL OFFICER | Common Stock | 2,220 | $38.93 | $86,425 |
| Patent |
|---|
Application Filling date: 4 Jun 2020 Issue date: 28 Jul 2022 |
Application Filling date: 27 Oct 2021 Issue date: 2 Jun 2022 |
Application Filling date: 27 Apr 2018 Issue date: 5 May 2022 |
Application Filling date: 27 Sep 2021 Issue date: 24 Mar 2022 |
Application Filling date: 26 Aug 2021 Issue date: 16 Dec 2021 |
Grant Filling date: 1 Nov 2017 Issue date: 26 Oct 2021 |
Grant Utility: Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R) Filling date: 18 Nov 2019 Issue date: 28 Sep 2021 |
Application Filling date: 13 Jul 2020 Issue date: 3 Jun 2021 |
Application Filling date: 19 Oct 2020 Issue date: 1 Apr 2021 |
Application Filling date: 15 Oct 2020 Issue date: 11 Feb 2021 |
| Insider | Compensation |
|---|---|
| Mr. Hamza Suria (1976) Pres, Chief Executive Officer & Director | $885,390 |
| Mr. Dennis M. Mulroy (1955) Chief Financial Officer | $448,810 |
| Dr. Paul F. Lizzul (1975) Chief Medical Officer | $339,760 |
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout
AnaptysBio: Despite Early Successes, Current Situation Does Not Impress
AnaptysBio: Upside Could Be Lying Ahead Very Nicely
Lantheus Holdings Rules The Medical Diagnostics Business World
-
What's the price of AnaptysBio stock today?
One share of AnaptysBio stock can currently be purchased for approximately $19.79.
-
When is AnaptysBio's next earnings date?
Unfortunately, AnaptysBio's (ANAB) next earnings date is currently unknown.
-
Does AnaptysBio pay dividends?
No, AnaptysBio does not pay dividends.
-
How much money does AnaptysBio make?
AnaptysBio has a market capitalization of 434.52M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 66.78% to 17.16M US dollars. AnaptysBio made a loss 163.62M US dollars in net income (profit) last year or -$1.59 on an earnings per share basis.
-
What is AnaptysBio's stock symbol?
AnaptysBio, Inc. is traded on the NASDAQ under the ticker symbol "ANAB".
-
What is AnaptysBio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AnaptysBio?
Shares of AnaptysBio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AnaptysBio's key executives?
AnaptysBio's management team includes the following people:
- Mr. Hamza Suria Pres, Chief Executive Officer & Director(age: 49, pay: $885,390)
- Mr. Dennis M. Mulroy Chief Financial Officer(age: 70, pay: $448,810)
- Dr. Paul F. Lizzul Chief Medical Officer(age: 50, pay: $339,760)
-
How many employees does AnaptysBio have?
As Jul 2024, AnaptysBio employs 117 workers.
-
When AnaptysBio went public?
AnaptysBio, Inc. is publicly traded company for more then 8 years since IPO on 26 Jan 2017.
-
What is AnaptysBio's official website?
The official website for AnaptysBio is anaptysbio.com.
-
Where are AnaptysBio's headquarters?
AnaptysBio is headquartered at 10770 Wateridge Circle, San Diego, CA.
-
How can i contact AnaptysBio?
AnaptysBio's mailing address is 10770 Wateridge Circle, San Diego, CA and company can be reached via phone at 858 362 6295.
-
What is AnaptysBio stock forecast & price target?
Based on 6 Wall Street analysts` predicted price targets for AnaptysBio in the last 12 months, the avarage price target is $55.33. The average price target represents a 179.60% change from the last price of $19.79.
AnaptysBio company profile:
AnaptysBio, Inc.
anaptysbio.comExchange:
NASDAQ
Full time employees:
117
Industry:
Biotechnology
Sector:
Healthcare
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
10770 Wateridge Circle
San Diego, CA 92121-5801
San Diego, CA 92121-5801
CIK: 0001370053
ISIN: US0327241065
CUSIP: 032724106
